CNS Pharmaceuticals Inc. CNSP Archives - Page 21 of 22

FridayOct 23, 2020 1:04 pm

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Moves Closer to IND Filing as Manufacturing of Lead Drug Candidate Commences

Berubicin Expected to Commence Trials for the Treatment of Glioblastoma, An Aggressive Form of Brain Cancer Currently Considered Incurable Production of Berubicin Begins in the U.S. and Europe Dual Manufacturing Facilities Engaged to Reduce Supply Chain Interruptions IND for Berubicin Could Be Filed by Year End CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) expects to have an Investigational New Drug Application (“IND”) ready for its lead drug candidate, Berubicin, by the end of 2020. An approved IND would give the biotech company, which is developing treatments for primary and metastatic cancers of the brain and central nervous system, the green light to…

TuesdayOct 20, 2020 10:06 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Completion of Manufacturing of Lead Drug Candidate

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, has completed the manufacturing process for Berubicin Drug Product. CNSP’s U.S. manufacturer, Pharmaceutics International Inc. ("Pii"), has finished manufacturing the drug, which is the company’s lead drug candidate for the treatment of glioblastoma multiforme (“GBM”), an aggressive form of incurable brain cancer. In an attempt to diversify its supply chain, provide for local accessibility of Berubicin and reduce COVID-19-related delay risks, CNS had implemented a dual-track drug product manufacturing approach that used two different manufacturers for…

MondayOct 19, 2020 12:20 pm

QualityStocksNewsBreaks – Why CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Is ‘One to Watch’

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system. A recent article discussing CNS Pharmaceuticals reads, “The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1…

TuesdayOct 13, 2020 2:00 pm

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Takes Another Step Closer to Q1 Launch of Brain Cancer Drug Trial

CNS Pharmaceuticals is a pre-clinical-stage developer of novel brain cancer-fighting drugs, including its lead candidate Berubicin The company is working to build on promising results from a 2006 Phase I trial, which provided 44 percent of its limited patient pool with clinically significant improvement in disease stability and one patient with a durable complete response (no evidence of any tumor remaining) for over 14 years CNS Pharmaceuticals expects to launch a pivotal Phase II trial of Berubicin at the beginning of next year and has been assembling a team of partner companies help with the trial CNS recently announced that…

MondayOct 12, 2020 9:48 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Highlights New Glioblastoma-Focused Segment Airing on Lifetime TV

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today highlighted a new segment from The Balancing Act titled, "Behind the Mystery," which will air on Lifetime TV and focus on glioblastoma. The segment, live this morning, follows the unique story of a glioblastoma patient and clinical insights regarding the rare and difficult-to-treat disease from Dr. Sigmund Hsu, a member of CNS Pharmaceuticals’ Scientific Advisory Board. In addition, a re-airing of the segment is planned for October 23, 2020. "It is encouraging to…

FridayOct 09, 2020 11:07 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Begins Manufacturing of Lead Drug Candidate in Europe

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that its European manufacturer, BSP Pharmaceuticals S.p.A. ("BSP"), has begun the manufacturing process for Berubicin Drug Product, its lead drug candidate for the treatment of glioblastoma multiforme (“GBM”). GBM is an aggressive form of brain cancer currently considered incurable. “Our preparations for filing an IND for Berubicin require continued execution in both our clinical and manufacturing initiatives,” CNS Pharmaceuticals CEO John Climaco said in the news release. “With the manufacturing of our…

MondayOct 05, 2020 12:51 pm

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Partnership with Imaging Specialists IAG Gives Tech Boost to Upcoming Brain Cancer Drug Trials

Clinical-stage biotech developer CNS Pharmaceuticals is working to demonstrate the potential effectiveness of its novel drug, Berubicin, in treating aggressive and rare brain cancer glioblastoma multiforme (“GBM”) CNS expects to launch Phase II trials of Berubicin later this year or in Q1 of 2021, building on promising results shown in initial trials One patient in the Phase I trial has remained cancer-free over the course of 14 years, and 44 percent of the patients who could be evaluated experienced a clinically significant positive response to Berubicin CNS’s laser-focused strategy for developing a GBM therapy is also leading the company to…

ThursdayOct 01, 2020 10:38 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Achieves Critical Milestone for Production of Lead Drug Candidate

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that its GMP manufacturer partner NCK A/S, received a Certificate of Analysis (“CoA”) for its Active Pharma Ingredient (“API”), clearing it for use in the production of Berubicin. CNS Pharmaceuticals previously announced entry into a contract with NCK A/S, a GMP manufacturer of complex drugs and the previous producer of Berubicin for Reata Pharmaceuticals, for the large-scale production of Berubicin, CNSP’s lead drug candidate for the treatment of glioma brain tumors. "We…

TuesdaySep 29, 2020 12:36 pm

CNS Pharmaceuticals, Inc. (CNSP) Expands Scientific Advisory Board with Leading Neuro-Oncology Expert, Dr. Patrick Wen, M.D.

Pivotal Phase 2 Berubicin trial expected to commence in Q1 2021 following planned IND submission in Q4 2020 CNS Pharmaceuticals also plans to begin pre-clinical work on Berubicin in connection with treatment for lymphomas, pancreatic, and ovarian cancers Brain tumor drug therapeutics market expected to reach $3.4 billion by 2025 CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, has expanded its Scientific Advisory Board by welcoming new member Dr. Patrick Wen, M.D., a leading neurology and neuro-oncology expert (https://ibn.fm/VJ6e9). Dr. Wen joins current Board members,…

FridaySep 25, 2020 1:14 pm

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is “One to Watch”

CNS Pharmaceuticals’ lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and currently incurable form of brain cancer. In a Phase I clinical trial of Berubicin in malignant brain tumors, 44% of patients experienced a statistically significant improvement in clinical benefit. In preclinical studies, the company’s second drug candidate, a novel DNA binding agent, was 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Industry reports estimate that the global brain…

Site Search

Company Search

Tag: CNS Pharmaceuticals Inc. CNSP